Lipigo 5 Tablet contains Rosuvastatin 5 mg, a potent lipid-lowering agent belonging to the statin class of medications. It is primarily indicated for the treatment of hypercholesterolemia and mixed dyslipidemia to reduce elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and triglycerides, while increasing high-density lipoprotein cholesterol (HDL-C). Rosuvastatin acts by selectively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to decreased cholesterol production in the liver and increased clearance of LDL cholesterol from the bloodstream. Lipigo 5 is prescribed as an adjunct to diet and lifestyle modifications, including exercise and weight control, to improve lipid profiles and reduce the risk of cardiovascular events such as myocardial infarction, stroke, and atherosclerosis. The recommended dosage is individualized based on patient response and risk factors, with careful monitoring of liver function tests and lipid levels during therapy. Common adverse effects may include headache, myalgia, abdominal pain, and nausea, while rare but serious risks involve myopathy and hepatotoxicity. Lipigo 5 should be used cautiously in patients with hepatic impairment or a history of muscle disorders and is contraindicated during pregnancy and lactation. Regular follow-up with healthcare providers is essential to ensure safety and efficacy.